pubmed.ncbi.nlm.nih.gov

Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials - PubMed

️Invalid Date

Review

Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials

C G H Dahlöf. Cephalalgia. 2006 Feb.

Abstract

A migraineur can claim to be an infrequent responder ('non-responder') to an oral triptan independent of which triptan he or she is presently using. Four trials of an alternative triptan (zolmitriptan/rizatriptan; eletriptan; naratriptan; almotriptan) in patients with a history of infrequent response to oral sumatriptan were compared and contrasted in terms of study design, patient characteristics, and efficacy and tolerability of the triptan under investigation. Unfortunately, none of the reported studies used an appropriate parallel design, which would have had the non-responding triptan (oral sumatriptan) in one arm and without encapsulation. While the four trials differed in terms of study design (open-label vs. placebo-controlled), definition of sumatriptan 'non-responder' (retrospective vs. prospective) and pain intensity at baseline (30% severe to 70% severe), all four demonstrated that lack of response to sumatriptan did not predict lack of response to an alternative triptan. Changing triptans resulted in 2-h pain-relief rates of 25-81% in patients with a history of poor response to sumatriptan. It can be concluded that migraine patients who respond infrequently to sumatriptan should be switched to a different triptan, as lack of response to one triptan does not predict likelihood of responsiveness to another. A review of the available evidence suggests that almotriptan may be one of the most appropriate choices for an alternative triptan.

PubMed Disclaimer

Cited by

European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure.
Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Uludüz D, Versijpt J, Ducros A, Gil-Gouveia R, Katsarava Z, Martelletti P, Ornello R, Raffaelli B, Boucherie DM, Pozo-Rosich P, Sanchez-Del-Rio M, Sinclair A, Maassen van den Brink A, Reuter U. Sacco S, et al. J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-z. J Headache Pain. 2022. PMID: 36224519 Free PMC article. Review.
Italian guidelines for primary headaches: 2012 revised version.
Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G, Pinessi L, Alessandri M, Antonaci F, Fanciullacci M, Ferrari A, Guazzelli M, Nappi G, Sances G, Sandrini G, Savi L, Tassorelli C, Zanchin G. Sarchielli P, et al. J Headache Pain. 2012 May;13 Suppl 2(Suppl 2):S31-70. doi: 10.1007/s10194-012-0437-6. J Headache Pain. 2012. PMID: 22581120 Free PMC article.
The Use of Neuroimaging for Predicting Sumatriptan Treatment Response in Patients With Migraine.
Wu JW, Lai PY, Chen YL, Wang YF, Lirng JF, Chen ST, Lai KL, Chen WT, Wu YT, Wang SJ. Wu JW, et al. Front Neurol. 2022 Jan 31;13:798695. doi: 10.3389/fneur.2022.798695. eCollection 2022. Front Neurol. 2022. PMID: 35173673 Free PMC article.
Diagnosis and management of migraine in ten steps.
Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lantéri-Minet M, Braschinsky M, Del Rio MS, Daniel O, Özge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M. Eigenbrodt AK, et al. Nat Rev Neurol. 2021 Aug;17(8):501-514. doi: 10.1038/s41582-021-00509-5. Epub 2021 Jun 18. Nat Rev Neurol. 2021. PMID: 34145431 Free PMC article. Review.
Treatment adherence among new triptan users: a 2-year cohort study in Taiwan.
Chen TB, Chen YT, Fuh JL, Tang CH, Wang SJ. Chen TB, et al. J Headache Pain. 2014 Aug 12;15(1):48. doi: 10.1186/1129-2377-15-48. J Headache Pain. 2014. PMID: 25117594 Free PMC article.

Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials - PubMed